$ADHD Added to the NASDAQ Biotechnology Index


Alcobra Added to the NASDAQ Biotechnology Index

 Alcobra Ltd. (ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome (FXS), today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq:NBI), effective upon market open on December 21, 2015.

The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. Companies listed on the NASDAQ Biotechnology Index must meet eligibility requirements, including minimum market capitalization, average daily trading volume, and seasoning as a public company, among other criteria. For more information about the NASDAQ Biotechnology Index visit www.nasdaq.com.

For more information about the NASDAQ Biotechnology Index, including eligibility criteria, visithttps://indexes.nasdaqomx.com/.

About Alcobra Ltd.
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including ADHD and FXS. For more information please visit the Company’s website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.

U.S. Investor Contacts
LifeSci Advisors, LLC
Michael Rice
[email protected]

Media Inquiries
Sam Brown, Inc.
Mike Beyer
[email protected]

Israel Investor Contact:
Alcobra Investor Relations
Debbie Kaye
+972-72 2204661
[email protected]


Please enter your comment!
Please enter your name here